Testimony Before the FDA's Endocrinologic and Metabolic Drugs Advisory Committee Regarding Liraglutide (Victoza) for Cardiovascular Risk Reduction (HRG Publication #2374)

June 20, 2017

View as PDF.

Public Citizen testified against the additional approval of liraglutide (Victoza) for reducing cardiovascular risk in diabetes patients because the clinical trial to support such approval failed to show any benefit in the 2,500 American subjects in the trial. The study only showed a significant benefit in non-U.S. subjects.

View Public Citizen’s previous work on liraglutide